USPTO Art Unit 1611 Prosecution Statistics

Art Unit Information

Art Unit: 1611
Group: 1610
Tech Center: 1600
Total Cases: 10,351
Last Active: August 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19309669NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOFAugust 2025December 2025Allow400YesNo
19278180LEFLUTROZOLE COMPOSITIONS OF MATTER AND PROCESSES FOR PREPARATIONJuly 2025October 2025Allow300YesNo
19254167AQUEOUS SUSPENSION SUITABLE FOR ORAL ADMINISTRATIONJune 2025December 2025Allow610YesNo
19209542CALCIUM OR MAGNESIUM CHLORIDE SALT-BASED COMPOSITIONMay 2025August 2025Allow320YesNo
190972841-NAPHTHALENYL AMINOETHYL SCHIFF BASE AND USE AS A DEATH LIGAND-1 INHIBITORApril 2025August 2025Allow401YesNo
19062274INHIBITION OF CANCER CELL VIABILITY BY NANOCOMPOSITES OF GRAPHITIC C3N4, Fe2O3, AND MgAl2O4February 2025June 2025Allow400YesNo
19060293URSOLIC ACID MORPHOLINE SALTFebruary 2025June 2025Allow310YesNo
19056265METHODS OF ADMINISTERING GAMMA-HYDROXYBUTYRATE COMPOSITIONS WITH DIVALPROEX SODIUMFebruary 2025December 2025Abandon1010YesNo
19027091INDANE-, INDENE-, AZAINDANE-, AND AZAINDENE-AMINES AS ACTIVATORS OF SEROTONIN RECEPTORSJanuary 2025January 2026Allow6020YesNo
19022909SLEEP-IMPROVING COMPOSITIONS AND METHODS OF USEJanuary 2025March 2025Allow200YesNo
19021929LEVODOPA DOSING REGIMENJanuary 2025June 2025Allow510NoNo
19022531LEVODOPA DOSING REGIMENJanuary 2025April 2025Allow300YesNo
19022122LEVODOPA DOSING REGIMENJanuary 2025April 2025Allow310NoNo
19021696LEVODOPA DOSING REGIMENJanuary 2025June 2025Allow510NoNo
19022256LEVODOPA DOSING REGIMENJanuary 2025July 2025Allow610NoNo
19020126COMPOSITIONS COMPRISING INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND APO-B SECRETIONJanuary 2025September 2025Allow800YesNo
19009519Compositions and Methods for Treating CNS DisordersJanuary 2025November 2025Allow1110YesNo
18973027SYSTEMS AND METHODS FOR PREPARING AND ADMINISTERING A HYDRATING SUPPLEMENT COMPOSITIONDecember 2024June 2025Allow610YesNo
18968148COMPOSITIONS AND METHODS FOR MUSCLE REGENERATION USING PROSTAGLANDIN E2December 2024March 2026Abandon1521NoNo
18967455COMPOSITIONS AND METHODS FOR TREATING DIABETESDecember 2024October 2025Allow1021YesNo
18955947SOLID POLYMORPHS OF A FLNA-BINDING COMPOUND AND ITS HYDROCHLORIDE SALTSNovember 2024July 2025Allow711YesNo
18944456AQUEOUS SUSPENSION SUITABLE FOR ORAL ADMINISTRATIONNovember 2024June 2025Allow710YesNo
18940954ENERGY DRINK COMPOSITIONNovember 2024August 2025Allow910YesNo
18934978PHARMACEUTICAL COMPOSITIONSNovember 2024April 2025Allow610YesNo
18915144READY-TO-USE SODIUM PHOSPHATES INJECTIONOctober 2024February 2025Allow410YesNo
18910781URSOLIC ACID MORPHOLINE AND DIETHANOLAMINE SALTSOctober 2024November 2024Allow100YesNo
18904150DELAYED RELEASE ORAL PHARMACEUTICAL COMPOSITIONOctober 2024October 2025Allow1220NoNo
18904951Constrained Ionizable Cationic Lipids and Lipid NanoparticlesOctober 2024May 2025Allow801NoNo
18897019Pathogenic Affinity Pathway of Infectious or Parasitic Organisms for Nanogram and Picogram Dosimetry Prophylaxis or CureSeptember 2024December 2024Allow300YesNo
18894811THERAPEUTIC METHODS USING BUPROPION HYDROBROMIDE TO TREAT MAJOR DEPRESSIVE DISORDERSeptember 2024March 2025Allow610NoNo
18823153LEVODOPA DOSING REGIMENSeptember 2024December 2024Allow310NoNo
18823575LEVODOPA DOSING REGIMENSeptember 2024April 2025Allow710NoNo
18817743LEVODOPA DOSING REGIMENAugust 2024February 2025Allow610YesNo
18814882USE OF CYCLODEXTRINS AS AGROCHEMICAL DELIVERY SYSTEMAugust 2024March 2026Allow1800YesNo
18802458LEVODOPA DOSING REGIMENAugust 2024February 2025Allow610YesNo
18802151LEVODOPA DOSING REGIMENAugust 2024April 2025Allow820YesNo
18798201COMPOSITIONS COMPRISING INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND APO-B SECRETIONAugust 2024July 2025Abandon1121NoNo
18785063IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONEJuly 2024September 2024Allow200YesNo
18785092IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONEJuly 2024September 2024Allow200YesNo
18783734PHARMACEUTICAL COMPOSITION FOR TREATING MIGRAINEJuly 2024March 2026Allow1900YesNo
18730659SINGLE-DOSE COSMETIC PRODUCT AND PROCESS OF MANUFACTURING THEREOFJuly 2024February 2025Allow700YesNo
18773898Transdermal Delivery of TetrahydrocannabinolJuly 2024December 2024Allow500YesNo
18763746THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF ANTI-CANCER AGENT(S) AND IMMUNE CHECKPOINT INHIBITOR(S)July 2024September 2025Allow1410YesNo
18763256NANOPARTICLE DRUG TARGETING JFK AND USE THEREOFJuly 2024February 2026Allow2000NoNo
18759349VIGABATRIN LIQUID PHARMACEUTICAL COMPOSITIONJune 2024March 2025Allow910YesNo
18751870INHALABLE HORMONE RECEPTOR AGONIST FORMULATIONSJune 2024July 2025Abandon1311NoNo
18723593A COMPOSITION FOR TREATING OCULAR INFECTIONS AND A METHOD OF PREPARATION THEREOFJune 2024February 2026Allow2000NoNo
18743016NANOCRYSTALLINE HYDROXYAPATITE/POLYURETHANE HYBRID POLYMERS AND SYNTHESIS THEREOFJune 2024September 2025Abandon1510NoNo
18739339PUERARIA LOBATA NANO-SILVER COMPOSITE HYDROSOL, PREPARATION METHOD AND APPLICATION THEREOFJune 2024November 2024Allow510NoNo
18737498MICROFLUIDIC DIALYSIS MODULE AND CONTINUOUS PURIFICATION METHOD FOR DRUG CARRIERS OR BIOMEDICINE USING THE SAMEJune 2024February 2026Allow2000YesNo
18732567SOLUBLE CURCUMIN AND ITS DERIVATIVESJune 2024December 2025Allow1820YesNo
18731605LEVODOPA DOSAGE FORMJune 2024January 2025Abandon810NoNo
18677521PHARMACEUTICAL COMPOSITION AND METHOD FOR SUPPRESSING DEGENERATIONMay 2024September 2025Allow1610NoNo
18673394IONIZABLE LIPIDSMay 2024February 2026Allow2000YesNo
18670599METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENTMay 2024March 2025Abandon1010NoNo
18670262DYE ENHANCED VISUALIZATION OF CATARACT SURGERYMay 2024December 2025Abandon1911NoNo
18669046MEDICAL COUNTER MEASURES INCLUDING DRY POWDER FORMULATIONS AND ASSOCIATED METHODSMay 2024January 2026Allow2010NoNo
18667826READY-TO-USE SODIUM PHOSPHATES INJECTIONMay 2024July 2024Allow200YesNo
18665149SLEEP-IMPROVING COMPOSITIONS AND METHODS OF USEMay 2024December 2024Allow710YesNo
18660160COMPOSITIONS OF NITRATES AND METHODS OF USE THEREOFMay 2024November 2025Allow1821NoNo
18708606LIQUID DRESSING FOR PROMOTING WOUND HEALINGMay 2024April 2025Allow1110YesNo
18707229SURFACTANT COMBINATION FOR AQUEOUS AGROCHEMICAL (CROP PROTECTION) SUSPENSION FORMULATIONS WITH HIGH SALT CONTENT AND LOW-CONCENTRATION OF SULFONYLUREA HERBICIDEMay 2024February 2026Allow2100NoNo
18653070METHODS FOR SHRINKING PITUITARY TUMORSMay 2024March 2025Allow1010YesNo
18652849NOVEL POTASSIUM CHANNEL INHIBITORSMay 2024April 2025Allow1201YesNo
18650142METHODS OF TREATING PAINFUL DIABETIC PERIPHERAL NEUROPATHYApril 2024February 2026Abandon2211NoNo
18650564ANTIBIOTIC-FREE ANTIMICROBIAL FEED ADDITIVES AND ANTIMICROBIAL COMPOSITIONSApril 2024December 2025Abandon2020NoNo
18650973METHODS FOR INCREASING SEED YIELD AND OIL SEED PRODUCTIONApril 2024August 2025Abandon1521YesNo
18650675ANTIMICROBIAL COMPOSITIONApril 2024July 2025Abandon1501NoNo
18649759NICOTINE TABLETApril 2024June 2025Allow1301NoNo
18647695ENHANCED FORMULATIONS, COMPOSITIONS AND METHODS FOR PEST CONTROLApril 2024October 2025Allow1730NoNo
18646994TANNIN-BASED ANTIPROLIFERATIVE PHARMACEUTICALApril 2024November 2025Allow1911NoNo
18645654DRUG-COATED BALLOON CATHETERS FOR BODY LUMENSApril 2024April 2025Allow1110NoNo
18644582Method for Treating Active Bleeding Using Biocompatible Hemostatic and Sealant CompositionsApril 2024January 2026Allow2020NoNo
18643713PARENTERAL NUTRITION CONTAINING TRACE ELEMENTSApril 2024March 2025Abandon1111NoNo
18642653SURFACTANTS FOR AGRICULTURAL PRODUCTSApril 2024February 2026Allow2221YesNo
18640949MICRONIZED EGGSHELL MEMBRANE PARTICLES AND THE USE THEREOF TO PROMOTE THE HEALING OF WOUNDSApril 2024April 2025Allow1210YesNo
18639748COMPOSITION COMPRISING OIL PALM PHENOLICS FOR USE IN THE TREATMENT AND PREVENTION OF COLON DISEASES AND FOR PROMOTING AND MAINTAINING GUT AND GENERAL HEALTHApril 2024March 2025Allow1110YesNo
18635375PYRAZINO[1',2':1,5]PYRAZOLO[4,3-B][1,6]NAPHTHYRIDINES COMPOUNDS AS CK2 INHIBITORSApril 2024July 2024Allow300YesNo
18634040LEVODOPA DOSING REGIMENApril 2024August 2024Allow410NoNo
18699326ADHESION PREVENTING MATERIAL FOR OPHTHALMIC APPLICATIONS, AND METHOD FOR PRODUCING SAMEApril 2024February 2026Allow2310NoNo
18628073HIGHLY CRYSTALLINE ALPHA-1,3-GLUCANApril 2024February 2025Allow1010NoNo
18627020SHEET-SHAPED MEMBERApril 2024June 2025Abandon1510NoNo
18697213LIPID NANOPARTICLE USED FOR DELIVERING NUCLEIC ACID TO BRAIN TISSUEMarch 2024February 2026Allow2310NoNo
18620876SUBSTITUTED 1,2,4-TRIAZOLES AND METHODS OF USEMarch 2024December 2025Allow2121YesNo
18619984COSMETIC COMPOSITIONS AND METHODS OF THEIR USEMarch 2024October 2025Allow1920YesNo
18616227EDARAVONE SUSPENSION FOR ORAL ADMINISTRATIONMarch 2024December 2025Allow2010YesNo
18615512COMPOSITIONS AND METHODS FOR ADMINISTERING PALTUSOTINE TO PATIENTS WITH HEPATIC IMPAIRMENTMarch 2024September 2024Allow610YesNo
18613281PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASEMarch 2024July 2024Allow400YesNo
18612793BIOACTIVE FLUID COMPOSITIONSMarch 2024May 2025Allow1420YesNo
18609857HYDROGELS AS CARRIERS OF ACTIVE INGREDIENTS AND METHODS OF PRODUCING THE SAMEMarch 2024December 2025Allow2110NoNo
18608226Glucocorticoid Particles and Their UseMarch 2024December 2025Abandon2101NoNo
18607376COMPOSITIONS FOR CONTROLLING PHYTOPLANKTON CONTAMINATIONMarch 2024August 2025Allow1710YesNo
18606860THERAPEUTIC USES FOR SODIUM THIOSULFATE FORMULATIONSMarch 2024March 2025Allow1220NoNo
18596096COMPOSITIONS FOR CONTROLLING A PLANT DISEASEMarch 2024October 2025Allow2011NoNo
18594338Blarcamesine co-crystals for the manufacture of pharmaceutical dosage formMarch 2024April 2025Allow1401YesNo
18592672SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINESMarch 2024July 2025Abandon1601NoNo
18687951TREATMENT OF WHITE FECES SYNDROME IN SHRIMPFebruary 2024November 2025Allow2100YesNo
18588191QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASEFebruary 2024June 2024Allow400YesNo
18589336Compositions, Kits, Methods and Uses for Cleaning, Disinfecting, Sterilizing and/or TreatingFebruary 2024March 2025Allow1320NoNo
18685618SELF DEGRADATION-TYPE CDK9 INHIBITOR PRODRUG AND LIPOSOME ENCAPSULATING SAMEFebruary 2024December 2025Allow2100YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1611.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
484
Examiner Affirmed
369
(76.2%)
Examiner Reversed
115
(23.8%)
Reversal Percentile
11.8%
Lower than average

What This Means

With a 23.8% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
1765
Allowed After Appeal Filing
273
(15.5%)
Not Allowed After Appeal Filing
1492
(84.5%)
Filing Benefit Percentile
1.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 15.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1611 - Prosecution Statistics Summary

Executive Summary

Art Unit 1611 is part of Group 1610 in Technology Center 1600. This art unit has examined 10,351 patent applications in our dataset, with an overall allowance rate of 39.3%. Applications typically reach final disposition in approximately 38 months.

Comparative Analysis

Art Unit 1611's allowance rate of 39.3% places it in the 3% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1611 receive an average of 2.54 office actions before reaching final disposition (in the 88% percentile). The median prosecution time is 38 months (in the 18% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for multiple rounds of prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.